Related Experiment Video
Updated: Jun 10, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Drug or vaccine?: selecting the appropriate treatment for malignant glioma patients
Xue-jun Dai1, Wei-jian Jiang, Wei-min Wang
1Department of Neurosurgery, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, Guangdong, People's Republic of China.
Abstract:
Malignant gliomas are the most common and aggressive form of brain tumour. Current combinations of aggressive surgical resection, radiation therapy and chemotherapy regimens do not significantly improve long-term patient survival for these cancers. Therefore, investigative therapies including tumour vaccines have targeted this devastating condition. This article reviews evidence and data on chemotherapy and immunotherapy for a personalized medicine approach in order to enable physicians to select the appropriate treatment for glioma patients. Dendritic cell- and peptide-based therapy for gliomas seems to be safe and without major adverse effects. Gene-modified vaccines have also shown promise in the treatment of malignant gliomas. The concept of 'personalized medicine' is currently important in oncology treatment development. Using a personalized medicine approach, it may be necessary to evaluate the molecular genetic abnormalities in individual patient tumours, and such findings should be the mainstay of immunotherapeutic strategies designed for the individual patient.
Insights
Personalized medicine, including dendritic cell, peptide, and gene-modified vaccines, shows promise for treating malignant gliomas. Evaluating individual tumor genetic abnormalities is key for effective immunotherapy strategies.
Area of Science:
- Neuro-oncology
- Cancer immunotherapy
- Personalized medicine
Background:
- Malignant gliomas are aggressive brain tumors with poor long-term survival despite standard treatments.
- Current therapies (surgery, radiation, chemotherapy) offer limited improvement for glioma patients.
- Investigational therapies, such as tumor vaccines, are being explored.
Purpose of the Study:
- To review evidence on chemotherapy and immunotherapy for a personalized medicine approach in glioma treatment.
- To guide physicians in selecting appropriate treatments for individual glioma patients.
- To highlight the role of molecular genetic evaluation in tailoring immunotherapeutic strategies.
Main Methods:
- Review of existing data and evidence on chemotherapy and immunotherapy for malignant gliomas.
- Focus on personalized medicine strategies tailored to individual patient tumor characteristics.
- Evaluation of safety and efficacy data for dendritic cell-, peptide-, and gene-modified vaccines.
Main Results:
- Dendritic cell- and peptide-based therapies for gliomas appear safe with no major adverse effects.
- Gene-modified vaccines demonstrate potential in treating malignant gliomas.
- Personalized medicine approaches are crucial for advancing oncology treatment development.
Conclusions:
- Personalized medicine, guided by molecular genetic analysis of individual tumors, is essential for optimizing glioma immunotherapy.
- Tailored immunotherapeutic strategies hold promise for improving outcomes in malignant glioma patients.
- Further research into personalized vaccine-based therapies is warranted.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...